Jeff Pierson

Jeff Pierson is an investor at Axalbion Therapeutics Limited, a clinical-stage pharmaceutical company focused on developing TRPM8 agonists for treating chronic cough and dry eyes.1 As an investor, Pierson likely plays a role in supporting the company's financial growth and strategic development.

Beyond his involvement with Axalbion, Jeff Pierson has a diverse professional background. He is described as a technology executive and fund investor. His experience extends to public service, indicating a career that spans both the private and public sectors.

Pierson is also noted for his entrepreneurial endeavors, having co-founded at least one venture. This suggests he brings not only investment expertise but also hands-on experience in building and scaling businesses to his role at Axalbion.

While specific details about his day-to-day responsibilities at Axalbion are not provided, his background in technology, investing, and entrepreneurship likely contributes valuable insights to the company's development of pharmaceutical treatments.